AZN is slumping, but Wall Street sees signs of long-term growth

Shares of AstraZeneca have been stuck in a short-term rut, refusing to trade above the $200 range for nearly a month and frustrating investors who’d come to expect steady gains from the healthcare giant.

But momentum might be starting to shift. Shares edged slightly higher on Tuesday before sinking back below even during the midweek session as analysts advise the company’s long-term growth story could still be intact.

As for whether the recent weakness is a potential buying opportunity or signs of deeper trouble, the data tells a complex story.

A mix of headwinds and tailwinds

Healthcare is increasingly viewed as a defensive sector with leadership potentially, especially if AI sentiment wanes and economic growth slows. But AstraZeneca is dealing with a few challenges that are weighing on sentiment.

Near-term pressure points include:

• Valuation concerns as shares trade around 29x earnings
• High research and development spending
• Investor caution after gains of roughly 130% over five years

Still, the company continues to build momentum, particularly in its oncology pipelines, which is one of the most valuable sectors in modern medicine.

One example is Enhertu, a cancer therapy developed with Daiichi Sankyo. The drug recently received “priority review” status from the FDA, which is an expedited process reserved for treatments expected to provide significant public benefit.

Clinical trials show the drug reduced the risk of cancer recurrence or death by 53%, delivered a 92.4% three-year disease-free survival rate, and outperformed the current standard therapy in multiple categories.

AstraZeneca is also advancing AZD0901, an oncology therapy now entering a Phase III trial for gastric cancers.

Wall Street’s emerging consensus

Even as short-term price swings cause some investor anxiety, the company’s expanding drug pipeline gives analysts cause for optimism. Despite the recent stock softness, institutional sentiment remains broadly positive:

• Analysts currently give AZN stock a “moderate buy” consensus rating
• Several firms maintain “buy” or “overweight” recommendations
• Long-term models suggest shares may be undervalued by up to 40%

And institutional investors are heavily involved, with large asset managers like Franklin Resources and Russell Investments holding significant positions.

None of that negates the risks associated with the name, however. Drug approvals are unpredictable and pharmaceutical companies rely heavily on regulatory decisions they can’t control.

But the broader trend is clear, with big money choosing to look past short-term volatility to focus on the promise of long-term plans.

With so many moving parts involved in bringing new drugs to the market, pharma stocks rarely move in straight lines. But history suggests that companies with strong drug pipelines and diversified treatment portfolios have the best chance of recovering from bumps in the road.